SAN

91.32

+2.01%↑

SHL.DE

49.4

+2.09%↑

ARGX

498.9

+2.63%↑

FRE

42.76

+1.09%↑

ONC.US

225.61

+2.68%↑

SAN

91.32

+2.01%↑

SHL.DE

49.4

+2.09%↑

ARGX

498.9

+2.63%↑

FRE

42.76

+1.09%↑

ONC.US

225.61

+2.68%↑

SAN

91.32

+2.01%↑

SHL.DE

49.4

+2.09%↑

ARGX

498.9

+2.63%↑

FRE

42.76

+1.09%↑

ONC.US

225.61

+2.68%↑

SAN

91.32

+2.01%↑

SHL.DE

49.4

+2.09%↑

ARGX

498.9

+2.63%↑

FRE

42.76

+1.09%↑

ONC.US

225.61

+2.68%↑

SAN

91.32

+2.01%↑

SHL.DE

49.4

+2.09%↑

ARGX

498.9

+2.63%↑

FRE

42.76

+1.09%↑

ONC.US

225.61

+2.68%↑

Search

Guerbet

Cerrado

19.88 -3.02

Resumen

Variación precio

24h

Actual

Mínimo

19.78

Máximo

20.7

Métricas clave

By Trading Economics

Ingresos

-5.9M

5.1M

Ventas

-3M

422M

P/B

Media del Sector

19.813

56.602

Rentabilidad por dividendo

2.35

Margen de beneficios

1.21

Empleados

2,778

EBITDA

-14M

47M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-11.15% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.35%

2.45%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

18M

267M

Apertura anterior

22.9

Cierre anterior

19.88

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Guerbet Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 23:40 UTC

Acciones populares

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 may 2025, 23:33 UTC

Principales Movimientos del Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 may 2025, 23:25 UTC

Principales Movimientos del Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 may 2025, 23:25 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 22:58 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 21:35 UTC

Ganancias

Cisco Systems Names Patterson as CFO, Patel as President

14 may 2025, 23:59 UTC

Charlas de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 may 2025, 23:49 UTC

Charlas de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 may 2025, 23:47 UTC

Charlas de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 may 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 may 2025, 23:10 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 23:07 UTC

Ganancias

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 may 2025, 23:00 UTC

Principales Noticias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 may 2025, 22:43 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 22:34 UTC

Ganancias

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 may 2025, 22:33 UTC

Ganancias

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 may 2025, 22:23 UTC

Principales Noticias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 may 2025, 22:15 UTC

Ganancias

Correction to Cisco Earnings Article -- WSJ

14 may 2025, 21:48 UTC

Ganancias

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 may 2025, 21:37 UTC

Ganancias

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Guerbet previsión

Precio Objetivo

By TipRanks

-11.15% descenso

Estimación a 12 Meses

Media 18.081 EUR  -11.15%

Máximo 18.085 EUR

Mínimo 18.085 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Guerbet Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

19.76 / 20.7Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.